Home›Drug Pipeline› Palmitoylation cycle emerges as preclinical target for mucosal healing in IBD
Palmitoylation cycle emerges as preclinical target for mucosal healing in IBDNew molecular targets could help treat inflammatory bowel diseases
Frontiers in MedicinePublished September 18, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Interpret palmitoylation-targeting agents as preclinical only; clinical efficacy and safety are not established.
This systematic review evaluates the palmitoylation cycle as a potential therapeutic target in inflammatory bowel diseases, including ulcerative colitis. The authors synthesize evidence on ZDHHC acyltransferases, depalmitoylases (APTs and PPTs), and FASN, and on agents such as 2-BP, ML348, and Palmostatin B.
The main finding is that targeting the palmitoylation cycle showed promise in preclinical models to restore barrier function and attenuate intestinal inflammation. No effect size, absolute numbers, or p-values were reported. The review proposes a conceptual framework and novel molecular targets for mucosal healing therapies independent of traditional immunosuppression.
Important limitations are acknowledged. Clinical efficacy and safety remain to be established, and the potential of these agents in IBD is currently supported primarily by in vitro and animal studies. Adverse events, serious adverse events, discontinuations, and tolerability were not reported. Funding or conflicts of interest were not reported.
Given the preclinical nature of the evidence, these findings do not support clinical use of 2-BP, ML348, or Palmostatin B in patients with IBD. The review is hypothesis-generating and identifies molecular pathways that require validation in human studies before any practice implications can be drawn.
How this fits prior evidence
This review extends prior coverage of barrier-directed strategies in IBD, including extracellular vesicle-based therapies that show potential for tissue repair and barrier restoration but lack controlled human efficacy data. It also aligns with the mTOR-glycolytic axis as a driver of inflammation and mucosal barrier dysfunction in ulcerative colitis, and with the limited evidence for ILC plasticity in UC compared with Crohn's disease. Like those findings, the palmitoylation data are preclinical, and clinical efficacy and safety remain to be established.
Living with inflammatory bowel diseases like ulcerative colitis can be incredibly hard on the body. Current treatments often rely on suppressing the immune system, but researchers are looking for new ways to heal the gut lining directly. They are focusing on a process called palmitoylation, which helps maintain the health of the intestinal barrier.
Researchers looked at three specific compounds: 2-BP, ML348, and Palmostatin B. In early laboratory and animal studies, these compounds showed promise in reducing inflammation and helping the gut barrier function. This approach aims to heal the tissue without relying solely on traditional methods.
It is important to remember that these results come from early research in labs and animals. We do not yet know if these treatments are safe or effective for people. More human trials are needed to see if these compounds can actually help patients in a clinical setting.
What this means for you:
New compounds show promise in early lab tests to reduce inflammation and repair the gut in inflammatory bowel disease.
Common questions
What are these new treatments for?
These treatments, including 2-BP, ML348, and Palmostatin B, are being studied for inflammatory bowel diseases and ulcerative colitis. They aim to reduce intestinal inflammation and improve the barrier function of the gut, which is the lining that protects your body.
Are these drugs safe to use for my condition?
It is not yet known if these treatments are safe for humans. The current evidence comes from laboratory and animal studies. Because clinical safety and effectiveness have not been established in people yet, you should talk to your doctor about your current treatment plan.
How do these treatments differ from current options?
Current treatments often rely on suppressing the immune system. These new targets focus on the palmitoylation cycle to promote mucosal healing. This approach aims to heal the gut lining through a different biological pathway than traditional methods.
Homeostasis of the intestinal mucosal barrier microenvironment is contingent upon the coordinated interplay among mechanical, chemical, and immunological barriers. Recent studies have demonstrated that protein S-palmitoylation, a dynamic and reversible lipid modification, holistically reprograms the intestinal mucosal barrier microenvironment. This is achieved by modulating the membrane localization of tight junction proteins (Claudins and ZO proteins) and E-cadherin/catenin complexes, the secretion and anchoring of MUC2, as well as the membrane recruitment and signaling activation of receptors such as TLR4, NOD2, and NLRP3. Dysregulation of this modification not only drives barrier collapse and chronic inflammation in inflammatory bowel diseases (IBD), such as ulcerative colitis, but also exacerbates pathological progression by modulating the phenotypic remodeling of innate immune cells, including macrophages and neutrophils. Targeting the palmitoylation cycle—including ZDHHC acyltransferases, depalmitoylases (APTs and PPTs), or upstream metabolic enzymes like FASN—using either the broad-spectrum inhibitor 2-BP or selective inhibitors (ML348 and Palmostatin B), has shown promise in preclinical models restore barrier function and attenuate intestinal inflammation. However, it is important to emphasize that the therapeutic potential of these agents in IBD is currently supported primarily by in vitro and animal studies, and their clinical efficacy and safety remain to be established. This review systematically proposes a conceptual framework for the “reprogramming of the intestinal mucosal barrier microenvironment by S-palmitoylation.” By integrating current evidence spanning from molecular modifications to barrier functions and from mechanistic insights to therapeutic strategies, we aim to provide novel molecular targets and a theoretical foundation for the development of mucosal healing therapies that are independent of traditional immunosuppression.
